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How is information communicated both within and between cells of living systems with high signal to
noise? We discuss transmembrane signaling models involving two receptor tyrosine kinases: the
ﬁbroblast growth factor receptor (FGFR) and the MET receptor. We suggest that simple dimerization
models might occur opportunistically giving rise to noise but cooperative clustering of the receptor
tyrosine kinases observed in these systems is likely to be important for signal transduction. We propose
that this may be a more general prerequisite for high signal to noise in transmembrane receptor
signaling.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
1. Cooperative assembly of multiprotein systems in cell signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
2. Fibroblast growth factor signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
3. MET receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
4. How general is clustering of receptors? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1101. Cooperative assembly of multiprotein systems in cell
signaling
How do cell regulation and signal transduction achieve the high
signal to noise required for efﬁcient response to the environment,
both locally in the tissue and more broadly for survival of the or-
ganism? Reductionists, including members of our molecular and
structural biology communities, have tended to exploit Occam's
razor and to assume the simplest model, for example theAscher), tlb20@cam.ac.uk
r Ltd. This is an open access articledimerization of receptor tyrosine kinases, is the mechanism for
receptor activation. Dimers are then often assumed to give rise to a
series of binary interactions, usually involving post-translational
modiﬁcation leading eventually to changes in transcriptional
regulation. This has reinforced the idea of signaling pathways,
rather like classical metabolic pathways, with signals being trans-
duced through “virtual wires” to give rise to major changes in cell
regulation. But can this really be a useful working model?
We have argued over the years that cell regulatory systemsmust
be more complex if they are to achieve high signal to noise
(Blundell et al., 2000). The cell membrane and the cytoplasm pro-
vide a very crowded environment where interactions would be
common and diffusion of molecules impeded. Binary interactions
would occur opportunistically giving rise to noise in the system. Onunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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would be less likely to form by chance, especially if they have many
components. Thus, we have argued that low-afﬁnity but speciﬁc
binary complexes leading to cooperative assembly of higher order
signaling complexes e often involving clustering e should be
selectively advantageous to signaling (Blundell et al., 2000). Such a
model is illustrated schematically in Fig. 1A.
Receptor clustering has often been observed and was ﬁrst pro-
posed as a basis of membrane receptor cooperative activation by
Levitzki in the 1970's (Levitzki, 1974; Levitzki et al., 1975). Later Bray
et al. (1998) argued that receptor clustering is an important
mechanism for controlling cell sensitivity (Bray et al., 1998).
Cebecauer et al. (2010) describe how clusters have functional ad-
vantages and argue that although diffusion is essential for
spreading information across an ‘open space’, it is “too inefﬁcient
and of too low ﬁdelity to be the main ‘driving force’ behind most
macromolecular interactions in cells” (Cebecauer et al., 2010).
Nussinov and colleagues have presented a model of a multivalent
network of dynamic proteins and lipids, with speciﬁc interactions
forming and breaking through transient, preorganized and coop-
erative proteineprotein interactions spanning the cell, rather than
stochastic, diffusion-controlled processes (Nussinov, 2013;
Nussinov et al., 2014).
We have recently described a similar cooperative assembly of
higher order signaling complexes for two essential intracellular
signaling pathways of eukaryotic cells: DNA double-strand-break
repair by non-homologous end joining (NHEJ) and the detection
and correction of defective attachments of chromosomes to the
kinetochore through assembly of the mitotic spindle checkpoint
(Bolanos-Garcia et al., 2012). In NHEJ spatial and temporal organi-
zation of more than ten components into multiprotein assemblies
involves recognition of DNA double-strand breaks by the Ku het-
erodimer, the recruitment of DNA-PKcs for signaling and DNA
ligase IV for DNA ligation. Indeed, very recently we have described a
further component, a scaffolding protein, PAXX, which alsoFig. 1. Twomodels for achieving efﬁcient signaling in multiprotein systems through coopera
several receptor tyrosine kinases, such as ﬁbroblast growth factor receptor (FGFR). In the cas
receptors. B) The other involves concerted folding and binding, as exempliﬁed by small pepti
an anchor residue followed by cooperative folding and further receptor interactions.contributes to end bridging (Ochi et al., 2015). Accurate DNA-
damage repair signaling appears to involve co-operative forma-
tion of complex assemblies.
Although signaling and regulatory molecular assemblies often
exploit preformed globular structures that bind through multiple
epitopes, other cooperative systems involve the recognition by a
globular protein of a ﬂexible protein, leading to concerted folding
and binding and the major interactions forming through a single
epitope (Fig. 1B). Such systems were probably ﬁrst recognized in
ﬂexible peptide hormones such as glucagon (Blundell, 1979; Sasaki
et al., 1975) and generalized for many intracellular systems (Dyson
andWright, 2002, 2005). Intrinsic local disordered regions (Dunker
et al., 1998; Gsponer and Babu, 2009) are often associated with
concerted binding and folding, partly because this environment
maintains the peptide in an unstructured but accessible form in the
crowded environment of the cell.
Such disordered regions are common features of hub proteins in
interactome networks (Dosztanyi et al., 2006; Dunker et al., 2005).
Examples of concerted folding and binding include the folding of
the peptide linking the BRCT domains of DNA Ligase IV onto the
coiled-coil region of XRCC4 (Sibanda et al., 2001), the interaction of
the ﬂexible C-terminus of Artemis with DNA Ligase IV (Ochi et al.,
2013) and the interaction of Rad51 with BRCA2 BRC repeats
(Pellegrini et al., 2002) during homologous recombination. In the
last of these examples the cooperative and stepwise nature of the
interaction is evident: a phenylalanine anchor of the BRC repeat
motif binds in a deep pocket in a fairly ﬂat area of the surface of
Rad51, an alanine of the BRC repeat -F-X-X-A- repeat displaces an
“unhappy water” from a smaller pocket (Huggins et al., 2011), and a
helical region of a BRCA2 BRC repeat docks onto Rad51 in a shallow
groove. The general model for all of these appears to be initial
binding of a large side chain into a deep pocket, usually followed by
interaction at a second and sometimes third pocket, forming a
cluster of small pockets (Fuller et al., 2009). Less conserved in-
teractions involving regions N- or C-terminal to the conservedtive binding events. A) One of these involves receptor clustering and appears to occur in
e of FGFR a secondary receptor, heparan sulfate, is obligatory, and leads to clustering of
de hormones and many intracellular systems, where recognition appears to be through
Fig. 2. Structures of complexes of FGFR with FGF and heparin. Left; a complex of FGF1 (green), FGFR2c (cyan/purple), and a heparin decamer (gray) forms an asymmetric complex
with one heparin monomer (Pellegrini et al., 2000; PDB ID: 1E0O). Right: a complex of FGF2 (green), FGFR1 (cyan/purple) and two heparin decamers (light/dark gray) form a
symmetric complex (Schlessinger et al., 2000; PDB ID: 1FQ9). A similar complex exists in the structure deﬁned by Pellegrini et al. (2000) but has only one heparin molecule, giving
rise to 2:2:1 stoichiometry.
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partner.
Here we are concerned with transmembrane signaling through
hormone and growth factor receptors. We discuss the receptor
tyrosine kinases, focusing on two receptors: the ﬁbroblast growth
factor receptor (FGFR) and the MET receptor. Both FGFR and MET
comprise an extracellular region that recognizes the growth factor,
a single transmembrane helical region and an intracellular kinase.
The four FGFR receptors bind members of the much larger growth
factor FGF family but require a secondary receptor, heparan sulfate,Fig. 3. Nanospray mass spectrometry of the complex between FGF1, FGFR2 and heparin d
mixing them in a 2:2:2 ratio (Harmer et al., 2004; Harmer et al., 2006). The complex contain
The mass spectrum for this complex shows peaks for FGF1 (A), FGFR2 (B), and an FGF1eFGF
the 2:2:1 ternary complex. Inset: comparison of observed peaks for the ternary complex (bl
FGF1:FGFR2:heparin complex (red). The data are much more consistent with the 2:2:1 ratio.
the observed masses expected due to carried solvent molecules.an extracellular proteoglycan linked to transmembrane proteins,
for biological activity. The MET receptor is activated by the hepa-
tocyte growth factor/scatter factor (HGF/SF) without a secondary
receptor, but the much smaller splice form HGF-NK1 does require
the secondary receptor, heparan sulfate.
2. Fibroblast growth factor signaling
Fibroblast growth factors (FGF1-23) with their receptors
(FGFR1-4) play central roles in cell proliferation, differentiation,ecamer. FGF1, FGFR2 and heparin were separately puriﬁed, and a complex formed by
ing two FGF and FGFR units was then separated using size exclusion chromatography.
R2eheparin ternary complex (D). Additional, minor peaks show dimers and trimers of
ack) with theoretical peaks for a 2:2:1 FGF1:FGFR2:heparin complex (blue) and a 2:2:2
The above table compares the observed and theoretical masses, with a slight increase in
Fig. 4. Proposed model for the development of an FGFR signaling cluster. A) Basal cell state. Heparan sulfate carrying proteins, for example glypicans (blue), present heparin sulfate
(red/purple) to FGFRs (green). FGFRs are likely to be bound to the high sulfation NS domains of heparan sulfate (purple), and will be bound intracellularly to their partner FRS-2
(dark green). B) When FGFs (orange) encounter the cell, they will rapidly bind to heparan sulfate (left). FGFs will ﬁnd optimal sites by rapid binding and release, forming dimers
across heparan sulfate oligomers (center). FGFRs will then bind to these, and will then activate (*; right: here, FGFRs are shown as dissociating from intracellular dimers). C) The
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Fig. 5. Functional map and domain structure of MET, the product of the c-met proto-oncogene and receptor for HGF/SF (Gherardi et al., 2003). Abbreviation, NT e the N-terminal
region; SEMA e the SEMA domain; IgG1e4 e the immunoglobulin like domain 1e4; TM e the transmembrane region; TK e the tyrosine kinase domain; CT e the C-terminal region.
The b-propeller model of the ligand-binding domain of MET (residues 33e516) viewed from the top and side is shown in the top inset. In the bottom inset the four IgG domains are
shown (residues 563e656 (purple), 657e741 (red), 742e838 (blue), and 839e928 (cyan)).
M. Blaszczyk et al. / Progress in Biophysics and Molecular Biology 118 (2015) 103e111 107survival and migration. They are inactive if the target cells are
grown in the presence of the sulfation inhibitor chlorate
(Delehedde et al., 2000), providing evidence for heparan sulfate as
an obligate secondary receptor; and differentially sulfated heparan
sulfate fragments show varying abilities to support signaling by the
various FGF paralogs (Ford-Perriss et al., 2002). Clustering of re-
ceptors is fundamental to FGFR signaling. Upon activation, FGFRs
cluster into endocytotic vesicles, and the faithful trafﬁcking of these
vesicles determines both the duration of signaling, and also the
impact on downstream effectors such as Erk (Auciello et al., 2013).
Similarly, clustering of FGFRs by NCAM in neural tissue acts to send
strong FGFR mediated signaling into the cell (Kochoyan et al.,
2008).
Much of the evidence for the structure of FGFR interactions
comes from in vitro studies of complexes of the extracellular
domainwith its ligand (FGF) and heparin, which models the effects
of heparan sulfate in vivo (Delehedde et al., 2002). X-ray studies
indicated the probable existence of a 2:2:2 complex in the crystals
(Fig. 2) (Schlessinger et al., 2000). Parallel crystallographic studies
with heparin moieties indicated two kinds of asymmetrical 2:2:1
FGF1-FGFR2-heparin decasaccharide complexes coexist in the
crystal packing (Pellegrini et al., 2000). One of these corresponds to
a FGFR-FGF 2:2 dimer, similar to that within the 2:2:2 complex of
Schlessinger et al. (2000), but with only one heparin and therefore a
2:2:1 complex; the other has a heparin molecule that bridges two
FGF1:FGFR heterodimers linking them into a 2:2:1 FGF1-FGFR2-
heparin complex (reﬂecting a structure showing FGF1 dimerized
on heparin (DiGabriele et al., 1998)), but with heparin interactinginitial complexes will then nucleate larger complexes, as more protein is driven into mem
idence supports the formation of larger complexes by the formation of multiple complexes
using the alternative, complementary methods suggested by Pellegrini et al. (2000) and Sch
phosphorylate FRS-2. FRS-2 then acts a center for recruitment of messenger proteins, for exa
high stimulation, the FGF-FGFR-heparan sulfate complexes will be internalized into endosodirectly with only one of the two receptors (Fig. 2). Detailed bio-
physical studies of the interaction of FGF1 and FGF2 with heparin
have indicated that trans-dimerization of FGFs by heparin octa-
saccharides and heparin mimetics is strongly thermodynamically
favored (Brown et al., 2013; Goodger et al., 2008; Robinson et al.,
2005; Saxena et al., 2010). Extension of these studies to include
the receptor (Brown et al., 2013) strongly supports a model where
FGF trans-dimerization drives receptor dimerization as envisaged
by Pellegrini and colleagues (Pellegrini et al., 2000). Further ana-
lyses using gel ﬁltration, nanospray mass spectrometry and
analytical ultracentrifugation (Harmer et al., 2004) demonstrated
that both 2:2 FGF:FGFR arrangements binding with heparin can be
observed in solution, albeit with one heparin molecule preferred in
each case (Fig. 3). Furthermore, more unusual higher order stoi-
chiometries such as 4:4:1 are seen using mass spectrometry. The
use of longer heparin and heparan sulfate fragments reveals that
fragments from sixteen saccharides can support binding of four
FGF1 ligands (Brown et al., 2013) and additionally four FGFR2 units
(Harmer et al., 2006), and we have suggested that these mirror
surface clustering (Harmer, 2006; Robinson et al., 2005). Given this
wealth of evidence for clustering of FGFRs in response to FGFs, we
propose an initial model for this clustering derived from these
studies to stimulate further research (Fig. 4).
3. MET receptor
MET is a tyrosine kinase receptor, encoded by the c-met proto-
oncogene, and activated by proteolytic processing of thebrane microdomains. These will include clathrin (black) coated pits. Experimental ev-
on single heparan sulfate chains (left), and the formation of linked complexes forming
lessinger et al. (2000) (right). The activated FGFRs will trans-phosphorylate, and then
mple GRB-2 (deep blue), phospholipase C (PLC; mauve) and STAT (light blue). D) With
mes, from where they will continue signaling until the late endosomal stages.
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extracellular portion of MET is comprised of six domains. The large
N-terminal extracellular MET domain, called a SEMA domain,
adopts a 7 bladed b-propeller fold (Fig. 5). The SEMA domain en-
compasses the whole a-subunit and part of the b-subunit. The
SEMA domain is homologous to domains found in the semaphorin
and plexin families (Gherardi et al., 2004; Siebold and Jones, 2013).
The cystine-rich domain following the SEMA domain is approxi-
mately 50 residues long and includes four disulﬁde bonds. This
domain is connected to the transmembrane helix via four
immunoglobulin-like domains (IgG), which are also found in
integrins, plexins and transcription factors. The intracellular region
of the MET receptor comprises a tyrosine kinase catalytic domain
ﬂanked by distinctive juxtamembrane and carboxy-terminal
sequences.
The MET ligand, hepatocyte growth factor/scatter factor (HGF/
SF), is produced as a single-chain precursor pro-HGF/SF and pro-
teolytically cleaved to form an active protein. The full length HGF/SF
comprises of the N-terminal domain, 4 kringle (K) domains fol-
lowed by an inactive serine proteinase homology (SPH) domain.
The activation cleavage site is located between the 4th kringle
domain and the SPH domain, with the two resulting chains forming
a disulﬁde-bridged heterodimer (Fig. 6A).
Both themature and immature forms of HGF/SF bind to the MET
receptor with the same afﬁnity. However, the conformational
changes required to induce signal transduction and tyrosine kinase
phosphorylation take place only upon mature HGF/SF binding
(Hartmann et al., 1992; Lokker et al., 1992). Two binding sites on the
SEMA domain of the MET receptor recognize HGF/SF, with the NK1
binding with higher afﬁnity than the binding of the SPH domain to
a second site (Fig. 6) (Lokker et al., 1994; Okigaki et al., 1992; Stamos
et al., 2004). Two other hotspots, one located between the cystine-
rich region and IgG1, and the other between the IgG2 and IgG3
domains, have been recently recognized by single domain antibody
library screening (Basilico et al., 2014).Fig. 6. The structure of HGF/SF. A) Schematic representation of a/b heterodimer of HGF/SF (
NT e the N-terminal end; N e the N-terminal domain; K1, K2, K3, K4 e the kringle domains
structure of NK1 head-to-tail homodimer, C) electrostatic potential (blue: positive charge; re
sulfate (spheres). Lysine and arginine rich patches of N domain bind hexasaccharide and teThere are two naturally occurring alternative splice forms of
HGF/SF: NK1 and NK2. NK1 (N-terminal domain and kringle1) acts
as an agonist of MET signaling while NK2 (N-terminal domain,
kringle1 and kringle2) acts as antagonist (Tolbert et al., 2010). To be
able to bind to MET receptor, both splice variants of HGF/SF require
the presence of heparan sulfate, heparin or dermatan sulfate
(Catlow et al., 2008). Full-length hormone does not need heparan
sulfate or dermatan sulfate to bind to its receptor, but requires its
presence for signal transduction (Catlow et al., 2008; Kemp et al.,
2006; Tolbert et al., 2010). Based on in vitro studies, pro-
teoglycans that exist on cell surface have been proposed as co-
receptors in MET signaling (Catlow et al., 2008).
The structure of NK1 is available both on its own and in complex
with heparin 14-mer (dp14) (1NK1 and 1GMO respectively) and in
both cases it can be found as head-to-tail dimer (Fig. 6BeC)
(Chirgadze et al., 1999, Lietha et al., 2001). Dimerization of NK1 in
the absence of heparin/heparan sulfate is a concentration induced
process that requires sub-millimolar protein concentrations.
However, in the presence of heparin NK1 dimerizes in the sub-
micromolar range, which is more likely to be physiologically
relevant.
Small angle X-ray scattering of the MET:NK1:heparanesulfate
complex revealed a 2:2:2 stoichiometry (Youles et al., 2008), indi-
cating that the complex exists in solution as a dimer. A similar
structure is observed in a low resolution crystal structure of
MET:NK1: heparan sulfate (M Blaszczyk, DY Chirgadze, MY Youles,
H de Jonge, L Kemp, A Sobkowicz, MV Petoukhov, M Zhou, L Iamele,
MA Nessen, D Di Cara, A Winter, M Strezlecki, HH Niemann, B
Mulloy, CV Robinson, DI Svergun, TL Blundell and E Gherardi, un-
published results) where MET dimer formation is mediated
through an NK1 dimer interacting via its K1 domain with the re-
ceptor's b-propeller (Fig. 7).
The crystal structures of the HGF/SF a-chain (NK4) and full
length HGF/SF in complex with heparan sulfate and MET indicate
that the full length HGF/SF (DY Chirgadze, TL Blundell, E Gherardi,two chain HGF/SF) with cleaved covalent bond between R494 and V495. Abbreviation,
1, 2, 3, 4; SPH e serine proteinase homology domain CT e the C-terminal end. B) Crystal
d: negative charge) mapped on van der Waals surface of NK1 in complex with heparan
trasaccharide heparan sulfate.
Fig. 7. A) Schematic diagram showing clustering of the MET receptor and HGF/SF as observed in the crystal structure of the MET receptor fragment (MET567) and full length HGF/SF
complex (manuscript in preparation, Chirgadze, Gherardi, et al.). B) Crystal structure representation of NK1-MET dimer (manuscript in preparation, M Blaszczyk, DY Chirgadze, MY
Youles, H de Jonge, L Kemp, A Sobkowicz, MV Petoukhov, M Zhou, L Iamele, MA Nessen, D Di Cara, A Winter, M Strezlecki, HH Niemann, B Mulloy, CV Robinson, DI Svergun, TL
Blundell and E Gherardi). Abbreviation, N e the N-terminal domain; K1, K2, K3, K4 e the kringle domains 1, 2, 3, 4; SPH e serine proteinase homology domain; SEMA e the Sema
domain of the MET receptor; CR e cystine rich domain of the MET receptor.
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cluster, which is consistent with possible clustering of the receptors
on the membrane (Fig. 7). The main contacts contributing to such
clustering come from the interactions between the SPH domain and
SEMA domain as well as between the NK1 and the SEMA domain.
This result agrees with previously proposed models of MET re-
ceptor activation (Niemann, 2013; Stamos et al., 2004).
Glycosaminoglycans play an important but undeﬁned role in
MET signaling. Proteoglycans on the surface of the cell can carry
from 1 to 100 saccharide residue chain (dp1-100) of highly sulfated
heparan sulfate (Esko and Lindahl, 2001; Knelson et al., 2014). In
addition heparan sulfate requires at least six saccharides length
chain to bind to HGF/SF or its splice variants, NK1 and NK2 (Lyon
et al., 2004). Computational modelling has suggested that multi-
valent ligands with more than 2 receptor binding sites help pro-
mote and induce clustering (Grochmal et al., 2013). Therefore,
proteoglycans with greater than 24 saccharide units could easily
mediate extensive clustering through binding to two or more MET
dimers.
The structure of the HGF/SF:MET complex shows that interac-
tion between MET and the a and b chain of HGF/SF could lead to a
higher oligomerization state. Heterotetramerization might serve
as a precursor of higher order clustering on cell surface, which
could be facilitated by proteoglycans with more than 24 saccha-
ride units that can act as clustering factors for already oligo-
merized molecules of MET receptor. This mechanism of action
could explain why the presence of heparan sulfate is necessary to
induce signaling.
Clustering of the MET receptor could provide a mechanism to
obtain appropriate signal to noise that allows recognition at a
cellular level and leads to macroscopic cell responses (invasion,
etc.). Such receptor clustering could be observed on the cell surface
as patches, islands or zones of activation as has been described for
type I interferon receptor (IFN) using dual color tracking and
localization microscopy (You et al., 2014).4. How general is clustering of receptors?
Clustering of transmembrane signaling receptors is difﬁcult to
deﬁne and, where it is, evidence is not often easily forthcoming that
it is central to signaling. For example, the structures of insulin re-
ceptors conﬁrm the roles of dimeric structures in transmembrane
signaling (De Meyts, 2015; Garrett et al., 1998; Menting et al., 2013,
2014), and recently, it has been identiﬁed that the phosphorylated
kinase domains of IR and IGF1R also speciﬁcally dimerize (Cabail
et al., 2015) through exchange of the juxtamembrane region next
to the kinase domain. This could also promote clustering of the
receptors. Indeed there is emerging evidence of clustering of the
insulin receptor (IR) (Winter et al., 2012). Winter et al. (2012) use
single particle tracking techniques to show that IR-insulin com-
plexes interact with specialized, cholesterol-containing membrane
microdomains and components of the actin cytoskeleton. Insulin
analogues have been shown to differently activate insulin receptor
isoforms and post-receptor signaling (Sciacca et al., 2010). A further
interesting possibility to be explored is whether the extent of
clustering could affect post receptor signaling biases. This could
explain the augmented mitogenic response and clinical failure of
AspB10-insulin which had a higher afﬁnity for the IGF-1 receptor
(Drejer et al., 1991; Milazzo et al., 1997), and a lower dissociation
rate from the insulin receptor (Hansen et al., 1996). This altered
afﬁnity could have conceivably altered the opportunity for and
extent of clustering, explaining the changes in signaling observed.
Studies of the effects of ligand mobility (Ketchum et al., 2014)
and spatial control of membrane receptor function using ligand
nanocalipers (Shaw et al., 2014) on receptor clustering are begin-
ning to shine light on the spatial organization that regulates
receptor-mediated signaling. Together with recent developments
in live-cell imaging at the sub-micrometer scale and object (parti-
cle) tracking of signalling clusters (Cebecauer et al., 2010) these
approaches are likely to transform our understanding of receptor
transmembrane signaling in the future.
M. Blaszczyk et al. / Progress in Biophysics and Molecular Biology 118 (2015) 103e111110Here we have discussed receptor clustering that appears to
occur in several receptor tyrosine kinases. We have described how,
in the case of FGFR, a secondary receptor, heparan sulfate, is
obligatory, and leads to clustering. Similar observations occur with
HGF/SF-NK1, where heparan sulfate is obligatory even for dimer-
ization. Full length HGF/SF, which binds through both NK1 and
serine protease homology domains, appears to crosslink receptors
in crystals and may also do so on the cell surface. In both NK1 and
HGF/SF heparan sulfate probably leads to higher order clusters. We
propose that this is likely to be a more general prerequisite for high
signal to noise in transmembrane receptor signaling.
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